FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide

In April, The New York Times proclaimed that a gen-AI-driven company that hawked compounded GLP-1 drugs was potentially on track to have $1.8 billion in 2026 sales. The paper also reported that the company, MEDVi, had generated $401 million in sales in 2025, saying it had been given access to unspecified company financials. By then,… The post FDA logs more than 1,700 adverse event reports…